Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00198484 | Evaluation of Vitrase as a Spreading Agent | PHASE3 | COMPLETED | 108 | — | — | Oct 1, 2004 | Feb 1, 2005 | Mar 14, 2013 | 18 | United States |
Physician evaluation of effectiveness of Vitrase as an adjuvant and overall satisfaction, via questionnaire;
| Arm | Type | Description |
|---|---|---|
| Vitrase | EXPERIMENTAL | ovine hyaluronidase injection 150 USP Units in 1 mL solution. Single dose of Vitrase will be administered as an adjuvant prior to ophthalmologic surgery |
| Name | Type | Description |
|---|---|---|
| Vitrase | DRUG | - |
Inclusion Criteria: * Scheduled for an ophthalmic surgical procedure Exclusion Criteria: * Documented history of hypersensitivity to hyaluronidase or any other ingredient in Vitrase * Known history of hypersensitivity reaction to bee or wasp venom * Needing enhanced absorption and dispersion of d...